New Accelerated Approval Guidance Underscores Need for Accountability | Sheppard Mullin Richter & Hampton LLP
[co-author: Julian Klein*] On December 5, 2024, just in time for the holidays, the U.S. Food and Drug Administration (“FDA” or the “Agency”) released a draft guidance titled “Expedited Program for Serious Conditions: Accelerated Approval of Drugs and Biologics Guidance for Industry” (the “Draft Guidance”).[1] FDA’s so-called “accelerated approval” program is designed to expedite the…